Spots Global Cancer Trial Database for ublituximab
Every month we try and update this database with for ublituximab cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma | NCT05152459 | Recurrent Folli... Refractory Foll... | Tazemetostat Ublituximab Umbralisib | 18 Years - | City of Hope Medical Center | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) | NCT03801525 | Chronic Lymphoc... Small Lymphocyt... | Ublituximab Umbralisib Venetoclax | 18 Years - | TG Therapeutics, Inc. | |
| Ublituximab + Ibrutinib in Select B-cell Malignancies | NCT02013128 | Chronic Lymphoc... Mantle Cell Lym... | Ublituximab Ibrutinib | 18 Years - | TG Therapeutics, Inc. | |
| Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma | NCT04783415 | Mantle Cell Lym... | Acalabrutinib Ublituximab Umbralisib | 18 Years - | City of Hope Medical Center | |
| Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma | NCT01647971 | Non-Hodgkins Ly... B-cell Lymphoma Waldenstrom's M... Marginal Zone L... Chronic Lymphoc... Small Lymphocyt... Primary Central... | Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | NCT04635683 | Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald... | Lenalidomide Ublituximab Umbralisib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of TG-1801 in Subjects With B-Cell Lymphoma | NCT03804996 | B-Cell Lymphoma | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | NCT02656303 | Chronic Lymphoc... | Ublituximab Umbralisib | 18 Years - | TG Therapeutics, Inc. | |
| Ublituximab + Ibrutinib in Select B-cell Malignancies | NCT02013128 | Chronic Lymphoc... Mantle Cell Lym... | Ublituximab Ibrutinib | 18 Years - | TG Therapeutics, Inc. | |
| A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304 | NCT02656303 | Chronic Lymphoc... | Ublituximab Umbralisib | 18 Years - | TG Therapeutics, Inc. | |
| Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax | NCT04016805 | Chronic Lymphoc... | Ublituximab Umbralisib Ibrutinib Venetoclax Acalabrutinib O... | 18 Years - | TG Therapeutics, Inc. | |
| Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | NCT04635683 | Recurrent B-Cel... Recurrent Extra... Recurrent Folli... Recurrent Grade... Recurrent Grade... Recurrent Grade... Recurrent Lymph... Recurrent Mantl... Recurrent Margi... Recurrent Nodal... Recurrent Splen... Recurrent Walde... Refractory B-Ce... Refractory Extr... Refractory Foll... Refractory Grad... Refractory Grad... Refractory Grad... Refractory Lymp... Refractory Mant... Refractory Marg... Refractory Noda... Refractory Sple... Refractory Wald... | Lenalidomide Ublituximab Umbralisib | 18 Years - | Ohio State University Comprehensive Cancer Center | |
| Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | NCT03671590 | Non Hodgkin Lym... Chronic Lymphoc... | TG-1701 Umbralisib Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia | NCT02612311 | Chronic Lymphoc... | Obinutuzumab Ublituximab TGR-1202 Chlorambucil | 18 Years - | TG Therapeutics, Inc. | |
| Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma | NCT04508647 | Marginal Zone L... Follicular Lymp... | Ublituximab Umbralisib | 18 Years - | University of Colorado, Denver | |
| Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) | NCT02301156 | Chronic Lymphoc... | Ublituximab Ibrutinib | 18 Years - | TG Therapeutics, Inc. | |
| Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma | NCT02793583 | Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Small Lymphocyt... | Ublituximab Umbralisib Bendamustine | 18 Years - | TG Therapeutics, Inc. | |
| Study of TG-1801 in Subjects With B-Cell Lymphoma | NCT03804996 | B-Cell Lymphoma | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL | NCT03379051 | Chronic Lymphoc... Non-Hodgkin Lym... | Venetoclax Umbralisib Ublituximab Lenalidomide | 18 Years - | TG Therapeutics, Inc. | |
| Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies | NCT03671590 | Non Hodgkin Lym... Chronic Lymphoc... | TG-1701 Umbralisib Ublituximab | 18 Years - | TG Therapeutics, Inc. | |
| Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma | NCT03828448 | Follicular Lymp... Small Lymphocyt... | Ublituximab Umbralisib | 18 Years - | TG Therapeutics, Inc. | |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia | NCT04806035 | CLL SLL Richter's Trans... Indolent Lympho... Follicular Lymp... Marginal Zone L... Aggressive Lymp... DLBCL Mediastinal Lar... MCL | TG-1801 Ublituximab | 18 Years - | TG Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
